CELYAD ONCOLOGY SA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.305 EUR | 0.00% |
|
+0.49% | -21.79% |
| 04-04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
| Sales 2022 | - | Sales 2023 | 102K 110K 8.76M | Capitalization | 16.16M 17.5M 1.39B |
|---|---|---|---|---|---|
| Net income 2022 | -40M -43.33M -3.43B | Net income 2023 | -8M -8.67M -687M | EV / Sales 2022 | - |
| Net cash position 2022 | 12.19M 13.2M 1.05B | Net cash position 2023 | 5.95M 6.44M 510M | EV / Sales 2023 | 100 x |
| P/E ratio 2022 |
-0.28
x | P/E ratio 2023 |
-1.19
x | Employees | 18 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Celyad Oncology SA
More recommendations
More press releases
More news
| 1 week | +0.49% | ||
| Current month | -6.15% | ||
| 1 month | -10.29% | ||
| 3 months | -18.23% | ||
| 6 months | -44.75% | ||
| Current year | -21.79% |
1 week
0.30
0.32
1 month
0.300.34
Current year
0.300.47
1 year
0.301.28
3 years
0.305.20
5 years
0.3018.50
10 years
0.3070.95
| Managers | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 23/07/07 |
David Georges
DFI | Director of Finance/CFO | - | 31/12/18 |
Eytan Breman
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 23/07/07 |
Hilde Windels
CHM | Chairman | 59 | 06/05/18 |
Serge Goblet
BRD | Director/Board Member | - | 31/12/07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/05/24 | 0.305 | 0.00% | 6 946 |
| 14/05/24 | 0.305 | -0.97% | 4,908 |
| 13/05/24 | 0.308 | -0.32% | 12,695 |
| 10/05/24 | 0.309 | -3.13% | 5,084 |
| 09/05/24 | 0.319 | +5.11% | 10,014 |
Real-time Euronext Bruxelles, May 15, 2024 at 12:12 pm
More quotes
Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Calendar
20/09/2024
- Q2 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.79% | 13.67M | |
| +29.03% | 49.18B | |
| -0.10% | 42.11B | |
| +48.26% | 40.37B | |
| -5.26% | 28.85B | |
| +11.48% | 26.09B | |
| -22.74% | 18.71B | |
| +9.06% | 13.26B | |
| +30.01% | 12.32B | |
| -1.51% | 11.99B |
- Stock Market
- Equities
- CYAD Stock
